Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FGF19 Analog as a Surgical Factor Mimetic That Contributes to Metabolic Effects Beyond Glucose Homeostasis
Alex M. DePaoli, Mei Zhou, Daniel D. Kaplan, et al.
Diabetes (2019) Vol. 68, Iss. 6, pp. 1315-1328
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Molecular physiology of bile acid signaling in health, disease, and aging
Alessia Perino, Hadrien Demagny, Laura A. Velázquez‐Villegas, et al.
Physiological Reviews (2020) Vol. 101, Iss. 2, pp. 683-731
Open Access | Times Cited: 300
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
Stephen A. Harrison, Guy Neff, Cynthia D. Guy, et al.
Gastroenterology (2020) Vol. 160, Iss. 1, pp. 219-231.e1
Open Access | Times Cited: 229
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Laurie L. Baggio, Daniel J. Drucker
Molecular Metabolism (2020) Vol. 46, pp. 101090-101090
Open Access | Times Cited: 222
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial
Stephen A. Harrison, Manal F. Abdelmalek, Guy Neff, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 7, pp. 603-616
Closed Access | Times Cited: 97
Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets
Joshua S. Fleishman, Sunil Kumar
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 77
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis
Mary E. Rinella, Hsiao D. Lieu, Kris V. Kowdley, et al.
Hepatology (2023) Vol. 79, Iss. 3, pp. 674-689
Open Access | Times Cited: 43
FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond
Stephen A. Harrison, Tim Rolph, Madeline Knott, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 562-576
Closed Access | Times Cited: 33
Targeting the FGF19–FGFR4 pathway for cholestatic, metabolic, and cancerous diseases
Xiaokun Li, Weiqin Lu, Alexei Kharitonenkov, et al.
Journal of Internal Medicine (2024) Vol. 295, Iss. 3, pp. 292-312
Open Access | Times Cited: 24
Metabolic Messengers: fibroblast growth factor 15/19
Raffaella Maria Gadaleta, Antonio Moschetta
Nature Metabolism (2019) Vol. 1, Iss. 6, pp. 588-594
Closed Access | Times Cited: 95
FGF19 and FGF21 for the Treatment of NASH—Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human
Emma Henriksson, Birgitte Andersen
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 72
Review article: therapeutic aspects of bile acid signalling in the gut‐liver axis
Benedikt Simbrunner, Michael Trauner, Thomas Reiberger
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 10, pp. 1243-1262
Open Access | Times Cited: 70
Effect of Bariatric Surgery on Metabolic Diseases and Underlying Mechanisms
Yu Ji, Hangil Lee, Shawn Kaura, et al.
Biomolecules (2021) Vol. 11, Iss. 11, pp. 1582-1582
Open Access | Times Cited: 67
Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases
Arun J. Sanyal, Lei Ling, Ulrich Beuers, et al.
JHEP Reports (2021) Vol. 3, Iss. 3, pp. 100255-100255
Open Access | Times Cited: 61
Fibroblast Growth Factor–Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications
Leigang Jin, Ranyao Yang, Leiluo Geng, et al.
The Annual Review of Pharmacology and Toxicology (2022) Vol. 63, Iss. 1, pp. 359-382
Open Access | Times Cited: 43
Management of metabolic-associated fatty liver disease: The diabetology perspective
Mohammad Sadiq Jeeyavudeen, Shahanas K A Khan, Sherouk Fouda, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 1, pp. 126-143
Open Access | Times Cited: 34
Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho
Alexandra Aaldijk, Cristy R.C. Verzijl, Johan W. Jonker, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 26
Research progress on the relationship between bile acid metabolism and type 2 diabetes mellitus
Yisen Hou, Xinzhe Zhai, Xiaotao Wang, et al.
Diabetology & Metabolic Syndrome (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 24
The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH
Rohit Loomba, Lei Ling, Duy M. Dinh, et al.
Hepatology (2020) Vol. 73, Iss. 1, pp. 126-143
Open Access | Times Cited: 67
Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
Gianluca Svegliati‐Baroni, Bárbara G. Patrício, Gessica Lioci, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 16, pp. 5820-5820
Open Access | Times Cited: 54
The Saga of Endocrine FGFs
Phuc Phan, Bibhuti Ballav Saikia, Shivakumar Sonnaila, et al.
Cells (2021) Vol. 10, Iss. 9, pp. 2418-2418
Open Access | Times Cited: 45
Intestinal FGF15 regulates bile acid and cholesterol metabolism but not glucose and energy balance
Nadejda Bozadjieva-Kramer, Jae Hoon Shin, Ziru Li, et al.
JCI Insight (2024) Vol. 9, Iss. 7
Open Access | Times Cited: 5
THE ROLE OF FGF19 IN METABOLIC REGULATION: INSIGHTS FROM PRECLINICAL MODELS TO CLINICAL TRIALS
Marcela Botelho de Carvalho, Gabriel Machado Chavez Passos Jorge, Luiza Wolf Zanardo, et al.
AJP Endocrinology and Metabolism (2024) Vol. 327, Iss. 3, pp. E279-E289
Closed Access | Times Cited: 5
Liver-targeting drugs and their effect on blood glucose and hepatic lipids
Amalia Gastaldelli, Norbert Stefan, Hans‐Ulrich Häring
Diabetologia (2021) Vol. 64, Iss. 7, pp. 1461-1479
Open Access | Times Cited: 31
Intestinal-derived FGF15 protects against deleterious effects of vertical sleeve gastrectomy in mice
Nadejda Bozadjieva-Kramer, Jae Hoon Shin, Yikai Shao, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 29
Pathology and Therapeutic Significance of Fibroblast Growth Factors
Oshadi Edirisinghe, Gaëtane Ternier, Thallapuranam Krishnaswamy Suresh Kumar
Targets (2025) Vol. 3, Iss. 1, pp. 5-5
Open Access
Page 1 - Next Page

Scroll to top